Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEMarc Humbert, K. Surrey, Raymond G. Slavin et al.|Allergy|2004Cited by 1.1k
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthmaMarek Kulus, Martin Blogg, A. Fowler Taylor et al.|Current Medical Research and Opinion|2010Cited by 92